Dr. Rüdiger Herrmann focuses his practice on key transactions in the biotechnology and pharmaceutical sectors. He has a wealth of experience advising national and international clients on mergers and acquisitions, licensing agreements, initial public offerings, intellectual property matters and private equity/venture capital transactions. He has a particularly strong background in dealing with life science matters in the US, Europe, China and Taiwan.
Rüdiger is an international speaker on biotechnology, pharmaceuticals, private equity and M&A topics, having lectured at Bio International, Bio Europe, Bio Equity, and the Venture Capital forum in London, among other conferences.
Advised uniQure on an exclusive strategic collaboration with Bristol-Myers Squibb*
Advised 4SC on a licensing and development partnership for its lead compound with Menarini*
Advised 4SC on a licensing and development partnership for cancer compound with Link Health*
Advised a Dutch biotech company on a commercialization agreement for gene therapy product and a co-development agreement with an Italian pharma company*
Represented Canada-based biotech company Resverlogix in a license and equity investment transaction with a Chinese public listed company Shenzhen Hepalink Pharmaceutical Co. for Resverlogix’s RVX-208 program*
Advised a leading German medical and pharmaceutical device company on its joint venture project in the Middle East and Russia*
Advised Lohmann Animal Health GmbH on its joint venture and license transaction with China Wuhan Sunhy Biotech Co., Ltd*
Represented PAION AG in its cross-border licensing transaction with China Yichang Humanwell Co., Ltd*
Advised Lohmann Animal Health GmbH on the establishment of a wholly Foreign Owned Enterprise (WFOE) in Shanghai, China*
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.